Not Signed In - Genta Receives Special Protocol Assessment From FDA For Randomized Trial Of Genasense(R) Plus Chemotherapy In Chronic Lymphocytic Leukemia
Sat, 07 Oct 2006 07:00 AM EST
... Genta Incorporated (Nasdaq: GNTA) announced that the Company's proposal for a randomized trial of Genasense(R) (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia (CLL) has completed Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). [click link for full article] ...
Related Topics
- Leukemia, Chronic Lymphocytic
- Chronic Lymphocytic Leukemia
- Leukemia
- Chemotherapy
- Clinical Trials
- Chronic lymphocytic leukemia cancer
- Myelogenous Leukemia, Chronic
- Leukemia, Chronic Myelogenous
- Chronic Myelogenous Leukemia
- Security Risk Assessment
- Acute Lymphocytic Leukemia (ALL)
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia cancer
- Chronic lymphocytic thyroiditis
- Leukemia, Childhood
- Childhood Leukemia
- Chronic Fatigue Syndrome
- Chronic Pain
- Pain - Chronic
- Chronic Diseases
email this page
print this page
bookmark this page
feedback on this page
